– USA, VA – ZielBio, Inc., an early-stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative drug discovery platform, today announced the appointment of industry veteran Dieter Weinand to its Board of Directors as the Executive Chair.
“We are excited to welcome Dieter Weinand to our board in this vital stage where we are expanding our development programs and our outstanding scientific and corporate teams,” said Founder and President, Dr. Kimberly Kelly. “Dieter is a proven executive in life sciences and has embraced our mission to discover actionable, new disease targets and to use that knowledge to develop truly transformational therapies.”
ZielBio’s lead candidate ZB131 is a proprietary humanized monoclonal antibody against cancer-specific plectin, a target that is highly expressed on the plasma membrane of multiple types of cancer cells, including several with high unmet need. ZielBio plans to launch its first clinical trial of ZB131 in late 2021.
Dr. Jason Dinges, investment advisor to Morningside Ventures and ZielBio director, commented, “It is especially validating to have an executive of Dieter’s caliber join us in advancing ZielBio’s compelling technology. His wealth of experience will help guide our business efforts as we move our lead oncology asset ZB131 into the clinic in 2021 and accelerate our pipeline.”
About Dieter Weinand
Mr. Weinand joins ZielBio with deep expertise in the pharmaceutical industry, currently also serving as chairman of the board of directors of Replimune Group Inc., which completed an initial public offering in 2018 (NASDAQ: REPL). Previously, Mr. Weinand served as the EVP of Primary Care and was a member of the Executive Committee at Sanofi. Before moving to Sanofi, Mr. Weinand was CEO and Chairman of the Board of Management of Bayer Pharma AG and member of the Management Board at Bayer AG. Prior to his work at Sanofi, Mr. Weinand held positions of increasing responsibility at Pfizer, Bristol Myers Squibb, and Otsuka. He has raised several hundred million dollars for biotech companies and cultivated strategic alliances between Bayer and Loxo Oncology and between Pfizer and Bristol-Myers Squibb.
“I was attracted to ZielBio’s groundbreaking ZielFind target discovery platform,” said Mr. Weinand. “I look forward to working with the board and this impressive team to develop transformational therapies for patients suffering from serious diseases.”
About ZielBio, Inc.
ZielBio is an early-stage biotechnology company that identifies novel disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform ZielFind combines the power of functional, high throughput screening with large content data analytics to identify high-value targets. ZielBio has a promising pipeline of therapies and targets, including lead asset ZB131, a proprietary humanized monoclonal antibody against cancer-specific plectin, a target identified through ZielFind.
For more information: https://www.zielbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
